Connect with us
A U.S. judge ruled that Novartis lacked grounds to suspend the launch of MSN's generic version of Entresto but ordered a temporary production halt pending Novartis'...
Baxter plans to sell its renal business by early 2025 to reduce debt, continuing its strategy of divesting subsidiaries, including a $3.857 billion sale of Biopharma...
Eli Lilly is expanding its presence with the opening of a 346,000-square-foot facility in Boston, which will house 500 scientists and the first East Coast location...
Crown Laboratories is acquiring Revance Therapeutics to expand its presence in the beauty market, offering $6.66 per share, an 89% premium. Revance, maker of the Botox...
Teva's first-half performance in Spain exceeds annual forecasts, with 2024 growth projected at 7.5%. The company has invested over €70 million in Spain since 2008, with...
Eli Lilly's first-half 2023 revenues surged 31% to $20 billion, driven by Mounjaro's $4.9 billion in sales, dominating the company’s earnings. Trulicity, in contrast, saw a...
JPMorgan Chase reduced its stake in Grifols to 3.111%, down from a previous 3.458%, with 0.256% in voting rights and 2.855% through financial instruments. This follows...
In the first half of the year, Novo Nordisk saw significant growth in sales, with Ozempic revenue up 36% to 56.685 billion crowns (€7.596 billion) and...
BioNTech's revenues plummeted 78.1% in the first half of 2024, down to €316.3 million, due to decreased demand for Covid-19 vaccines and a seasonal sales lull....
According to the results presented by the pharmaceutical giants to the National Securities Commission (CNMV), the revenues of these five companies also rose in the first...
 |
|
 |  |
 |
|